NRT competition
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's NDA for its smoking cessation drug varenicline tartrate has been granted a six-month priority review by FDA, the firm announces Dec. 21. The product would be marketed as an Rx drug under the brand name Champix if approved. According to Pfizer, the brain's nicontinic receptor triggers a sense of satisfaction when nicotine is inhaled, but the effects recede quickly, creating a cycle of craving and withdrawal. Varenicline is designed to activate the nicotinic receptor to "reduce both the severity of the smoker's craving and the withdrawal symptoms," the firm maintains. Pfizer notes that priority reviews are assigned to drugs "that may provide a significant therapeutic advance over existing therapies." The drug's NDA was submitted in November...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.